Clinical Trial Update: Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ponatinib in lung cancer patients preselected by predictive biomarkers; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Lung
• Extensive-stage Small Cell Lung Cancer
• Limited-stage Small Cell Lung Cancer
• Non-small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Ponatinib (ponatinib)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-02-11